This article provides a structured, founder experience-based framework for building resilient and scalable ventures at the frontier of science and technology. Drawing on lessons from startup creation, IPOs, and corporate acquisitions across Japan, the United States, and global markets, the paper outlines essential strategies for founders navigating deep tech fields such as AI, advanced materials, energy, and pharmaceuticals.

The authors emphasize the critical role of early strategic design — anchored in a Lean Canvas, Target Product Profile (TPP), and Proof of Concept (POC) — to ensure intellectual property strength, market differentiation, and investor readiness. They highlight the importance of a well-structured business plan, effective financial staging from seed to Series C, and governance mechanisms that balance scientific innovation with managerial discipline. Particular attention is given to the inventor–management relationship in university originated startups, where misaligned roles often hinder commercialization.

The work further explores IP strategy in the age of generative AI, optimal equity retention and incentive systems, and the emergence of capital efficient models such as Hardware-as-a-Service (HaaS) and data-driven monetization. It connects technical validation with financial modeling— through DCF, NPV, and market sizing analyses—to guide founders toward sustainable growth and credible exits via licensing, acquisition, or IPO.

Ultimately, the paper distills a comprehensive roadmap for transforming deep scientific discoveries into globally competitive enterprises. It underscores that success in deep tech arises not merely from innovation itself, but from disciplined execution, sound governance, and the thoughtful orchestration of capital, talent, and intellectual property.

This document offers strategic guidance for entrepreneurs seeking success in deep tech startups across fields such as AI, advanced materials, chemicals, energy, and drug discovery. Drawing on hands-on experience in launching startups, navigating public listings, and executing corporate acquisitions in both the United States and Japan— and more broadly, across global markets—the authors distill key principles for building resilient, high-impact ventures. Acknowledging the unique challenges of founding a company from the ground up based on breakthrough experimental data, this work shares insights aimed at helping founders overcome those hurdles. Grounded in the belief that long-term success begins with a well-designed entry point and process, the content emphasizes the importance of so-called “entry strategies.” With clarity and conciseness, it seeks to highlight essential considerations, offering a practical reference for aspiring founders at the frontier of innovation.

Whether your startup operates in deep tech or another domain, the first step every entrepreneur should take is to thoughtfully complete the Lean Canvas (Figure 1). Carefully working through each section lays a strong foundation for strategic clarity and effective execution. One practical approach is to use sticky notes to populate the canvas with well considered responses and clearly defined goals. Leveraging AI tools can streamline the creation process and save valuable time. A Lean Canvas tailored for the drug discovery sector is shown in the lower part of the figure. Among intangible assets, patents and know-how — collectively referred to as intellectual property (IP) — form the most critical foundation. However, their true value hinges on the quality of the Target Product Profile (TPP).

This is because any product brought to market will inevitably be compared against competitors, making the originality of its development and its market potential key factors in its evaluation. This approach is broadly applicable across sectors including biotech, cleantech, advanced materials, quantum, and AI hardware. The TPP objectively shows how your product will be differentiated from standard marketed product or competing product in development; beyond testing significance, the TPP ultimately informs the product label after marketing. By drafting the TPP early on, startups lay the groundwork not only for IP creation but also for potential partners. Completing the Lean Canvas is extremely important because — unlike ordinary small and medium-sized enterprises (SME) — it frames the enterprise as a business with a global market perspective (Figure 2). Analyzing the Lean Canvas provides a clear snapshot of where your company stands — particularly in terms of exclusivity, originality, and differentiation. It serves as a strategic lens to assess whether these core attributes are firmly embedded. By mapping capital requirements alongside projected revenue growth, one effectively gauges the foresight and scalability of the business. Startups are expected to move swiftly and embrace innovation. Depending on the substance of the TPP, both revenue potential and company valuation can be significantly amplified (Figure 3).

How is your business plan structured?

Before presenting your company to investors, you must first prepare a well-crafted business plan. Standard components typically include: the background (defining the problem), vision and mission, competitive advantage, key achievements (including any patents filed), a pipeline overview, market potential, financial projections, organizational and personnel plans, a capital strategy formation
roadmap, and more. When drafting, be mindful of the clarity, coherence, and strategic alignment of each section. AI tools can also assist in streamlining the planning process and enhancing the quality of your business plan.

1. Prepare a concise 1–3 page Executive Summary (non-confidential) alongside a more detailed, confidential report. When presenting your business to external stakeholders, begin with the non confidential overview to establish context; if deeper
   engagement is warranted, follow up with the full confidential report. While many founders rely solely on presentation slides, investors pay close attention to whether the business narrative is clear, compelling, and well-structured. They also assess the presenter’s character and communication style as indicators of credibility, resilience, and leadership potential.
2. The mission defines what the company is doing today, while the vision articulates the desired future destination. To bridge the gap between present and future, it’s essential to develop a clear roadmap— and execute it with discipline. All relevant strategic
   information should be consolidated into a well structured PowerPoint deck for ease of presentation and delivery.
3. Financial planning for research-driven ventures requires careful consideration of both medium- to long-term expenditures and potential revenue streams. Early-stage income is typically sourced from research grants and collaborative research fees,
   while operational sustainability depends on raising capital from angel investors and venture capital firms. Executing staged financing rounds — Series A, B, and C — with stepwise increases in valuation signals that the business is progressing according
   to plan. Within the capital strategy, securing Proof of Concept (POC) for a research seed is a critical milestone. It enables access to Series A funding, facilitates joint development with external partners, and opens the door to licensing agreements (typically out-licenses).

A comprehensive plan should be in place to address all of these elements. In drug discovery, such timelines are generally described as spanning two to four years. If initial results stem from a simple experiment, the next step is to demonstrate efficacy through in vivo studies in animal models. To assess the scale and potential of the opportunity, some investors prefer to review the Total Addressable Market (TAM), Serviceable Available Market (SAM), and Serviceable Obtainable Market (SOM). In early stage companies, investor focus tends to center on TAM and the team — that is, the magnitude of the opportunity and the team’s ability to execute against it. Prior to raising a Series A round, some startups issue convertible notes or SAFEs (Simple
Agreements for Future Equity). These instruments typically include an interest rate (often tied to the prime rate), a discount to the Series A valuation upon conversion (usually 15–20 percent), and a maturity period of approximately 2–3 years. This approach was popularized by Y Combinator as a founder-friendly alternative to traditional convertible notes.

4. In the biotech and pharmaceutical sectors, human Proof of Concept (POC) is typically established during Phase II clinical trials, making it a relatively late-stage milestone. Preparatory steps include demonstrating safety through general toxicology studies, as well as validating efficacy and pharmacokinetics/ pharmacodynamics (PK/PD) in disease-model animals. However, patient safety and efficacy often diverge from animal results. Preclinical studies are conducted within narrow biological parameters — limited not only in scale but also in sensitivity and metabolic function — so therapeutic thresholds can vary widely, and human outcomes cannot be reliably predicted from animal data alone.

To improve the likelihood of demonstrating efficacy in clinical trials, it is essential to conduct studies under rigorously designed clinical protocols. This is far from straightforward — drug response can vary significantly depending on patient severity. For instance, certain therapies may elicit stronger effects in severely ill patients than in those with milder symptoms. The societal impact of drug discovery is realized only when a therapy is approved and brought to market. Yet it is rare for a startup to reach that point alone;securing a partner willing to shoulder the financial burden is essential. Meaningful progress requires sustained dialogue with advisors and subject-matter experts throughout the development journey.

In university-originated startups, a common challenge across countries is the relationship between the inventor — often a professor or researcher — and the executive team. It is not uncommon for inventors to be appointed as CEOs or board directors at the time of company formation; however, such arrangements often compromise long-term viability.
The main reasons include:

1. Having an exclusive license agreement in place does not eliminate ambiguity over the ownership of subsequent inventions — particularly when the inventor continues to influence the scientific direction. This can raise questions about whether newly generated intellectual property belongs to the university or the company and may inadvertently shape or limit the startup’s strategic flexibility.
2. Increased risk of compliance violations due to conflicts of interest between the university and the startup—particularly when the inventor maintains dual roles or overlapping responsibilities. Such arrangements can blur the boundaries between academic and commercial interests, complicate decision-making, and expose both entities to regulatory scrutiny or reputational risk.
3. Insufficient role delineation between the inventor and the CEO can lead to misaligned priorities and decision-making friction, ultimately weakening the company’s ability to execute its business strategy.

Inventors should focus on contributing as scientific advisors rather than getting involved in daily operations. If they serve as directors, their term should be limited, with a clear plan to shift into an advisory role. When inventors dominate management, decisions often become overly focused on their own technology, which can hinder progress. To build a strong organization, appoint a CEO with real leadership — not someone who simply follows the inventor, but someone who takes ownership, exercises sound judgment, and unites the team. The board should consist of trusted individuals, and having an odd number of directors may help prevent deadlocks. Advisory boards for R&D and business development — featuring inventors and external experts — can provide valuable support. Including international members also strengthens the foundation for global expansion. Behind every successful startup is clear leadership and well-defined roles. Reading case studies isn’t enough. Founders should actively seek conversations with experienced professionals — especially those who’ve faced failure — and consult multiple independent experts. This cultivates objective thinking and greatly improves the chances of successful commercialization.

When shaping capital policy, it’s beneficial for the CEO and board to retain at least 40 percent of total shares — both issued and potential — until the IPO. This ownership level supports stable leadership and builds investor trust. Growth should be tied to clear performance milestones, aiming to steadily increase company valuation. To strengthen governance, it’s effective to set up advisory boards with external experts. Separate committees for R&D and business development — each with independent specialists — can offer targeted support. Including international members also helps position the company for global expansion. Running a startup demands significant capital. Stock options, especially stock acquisition rights, are a valuable tool. They can attract and retain talent, reward advisors and executives, and even replace upfront licensing fees for university originated IP such as patents.

Startups should secure core patents and also protect trademarks and logos as part of a broader brand strategy. These assets contribute to long-term value and strengthen the company’s identity. Given the complexity of IP management, hiring in-house specialists is ideal. If that’s not feasible, outsourcing to patent attorneys or law firms is common. Patent oversight is essential not only for securing rights but also for checking potential conflicts with existing technologies and assessing freedom to operate. When converting domestic patents to international PCT filings, costs can be high — so precise evaluation is critical. As filings grow, companies should regularly review and adjust their list of designated countries. Branding decisions, including technology naming, product logos, and trademarks, also fall under IP strategy.

1. Inventorship: Under current patent law, only human beings can be listed as inventors. Even if generative AI contributes ideas, inventorship is determined by whether a person made a creative contribution. AI itself cannot qualify.
2. Confidentiality: Entering unpublished invention details into cloud-based AI tools poses a risk of information leakage. To protect trade secrets, companies should avoid inputting sensitive data into open systems or use AI tools within secure internal environments.
3. Disclosure Accuracy: Patent documents must meet legal standards for clarity and enablement. AI generated technical content may lack consistency or scientific rigor, so expert review is essential. When multiple people collaborate using AI, inventorship and copyright ownership must be clearly defined.

Generative AI is increasingly used in drafting patents and IP documents. However, its use raises key concerns.

Deep tech refers to breakthrough technologies — often involving new processes or equipment — that solve problems once thought unsolvable. For example, advanced robotics with high degrees of freedom can now replicate human motion and perform complex tasks in manufacturing and assembly. When evaluating deep tech investments, payback period is key: how quickly customers and startups recover their costs. A return within one year is considered excellent. Combining hardware and software often shortens this timeline, while the data generated can unlock new revenue streams. AI further amplifies this value by enhancing data generation and utilization.

In sectors like telecom, devices offer fast paybacks and produce large volumes of monetizable data. In areas like recycling, returns depend on the value of recovered materials—such as gold from e-waste, metals from auto manufacturing, or textiles from discarded fashion. These “waste-to-value” models blend deep tech (equipment-driven) and clean tech (process-driven), shaping unit economics and pricing strategies. Revenue from deep tech can come not only from equipment sales but also from recurring models like SaaS or HaaS. In these cases, companies retain ownership, install the product at the customer’s site, and charge monthly fees—creating stable, high margin income. Investors favor these models for their predictable cash flow. Importantly, scaling such models doesn’t always require large equity funding. Once the technology matures, startups can tap into specialized debt options—like equipment leasing or revolving credit lines. This mix of innovation and smart financing makes deep tech ventures both capital-efficient and scalable.

-------------------------------------------------------------------------------------------------------------------------------------------------

FIGURE 5. - Financial Forecast
Key Contracts:

• Investment agreement
• Stock Option Allocation Agreement
• Technology Transfer Agreement
• Joint Research and Development Agreement
• Manufacturing and Supply Agreement

Key Terms
Exercise stock price (tax-qualified price), Ownership of results and intellectual property, Supply price, Net sales, Royalty rate, Milestones payment, Trade secrets, Termination, Change of control

-------------------------------------------------------------------------------------------------------------------------------------------------

The main types of contracts a startup will enter into and the important clauses are shown in Figure 5. In negotiations for product out-licensing, the important points are to select a trustworthy partner and to set mutual goals. Ideally, partners should be those with whom you would share benefits even without a contract; nevertheless, circumstances may change after contracting. Therefore, arrangements for post termination handling are also important.

Exit strategies — such as joint development or licensing deals with large companies — become viable once foundational steps are in place. This pattern aligns with many successful startup cases. To sustain growth, company valuation becomes critical. Valuation includes both intangible assets like IP and know-how, and tangible assets shown on financial statements. A common method is the Discounted Cash Flow (DCF) approach, which calculates present value based on future Free Cash Flow (FCF). For investment decisions, Net Present Value (NPV) is often used. NPV compares the present value of expected returns with the initial investment, factoring in risk via a discount rate. In licensing negotiations, product sales forecasts are also evaluated using NPV.

For startups, “success” often means executing a strong exit—via IPO or acquisition. If the company grows substantially, it may enter a maturity phase through acquiring other firms or in-licensing new products. This is especially true for ventures built around their own original technologies. In contrast, startups that begin with in-licensed products tend to pursue further licensing or acquisitions. Startups introducing proven overseas products into the domestic market often have high success rates— precisely because original innovation is difficult. Yet many founders still choose this path, driven by the hope of solving unmet medical needs and contributing to society. In a growth-driven economy, such efforts — even if they fail — should be respected, not criticized. In addition to DCF, comparative analysis is used when data on similar companies is available, though such benchmarks are often limited.

Deep tech companies operate in high-risk, high reward environments. While success is hard to predict early on, its likelihood can be improved through rigorous evaluation and strategic planning. For startups, the journey often begins with refining “seeds” from universities or research institutions. This process forms the core of the business. Along the way, it’s essential to validate key elements — such as IP, management structure, TPP, and POC. These steps are critical for securing licensing deals and attracting major investment. The greatest challenge for deep tech startups is making fast, forward-looking decisions in a complex and uncertain landscape. Yet, the lessons learned through this process — both strategic and operational — often pave the way for successful exits, such as IPOs or acquisitions.